Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.

NCT07227870 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT07227870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07227870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.
Lead sponsor
Philogen S.p.A.
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
February 28, 2031
Enrollment
92 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced basal cell carcinoma